Drug Profile
Propofol - Cuda Pharmaceuticals/Ligand Pharmaceuticals
Alternative Names: Captisol-enhanced Propofol; CE-Propofol; CudafolLatest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Cuda Pharmaceuticals; Ligand Pharmaceuticals
- Class General anaesthetics; Phenols; Small molecules
- Mechanism of Action GABA A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Anaesthesia
Most Recent Events
- 28 May 2022 No recent reports of development identified for phase-I development in Anaesthesia(In volunteers) in USA (IV, Injection)
- 28 Feb 2020 No recent reports of development identified for phase-I development in Anaesthesia(In volunteers) in USA (IV, Injection)
- 31 Dec 2019 Phase-I development is ongoing in Anaesthesia (In volunteers) in USA (IV, Injection)